Clinical Trial Search Results

Filter Results

Age group

Category

Primary purpose

Study type

Location

Search results

You can use the filters to refine your search.

Displaying 1 - 20 of 26

Open Actively Recruiting

Early Lipid Accumulation and Cardiac Allograft Vasculopathy in Heart Transplant Recipients

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Danielle Campbell
Open Actively Recruiting

Virtual Reality Experience for Stress Reduction in Cardiology Patients

The purpose of the research is to evaluate the feasibility and scalability of delivering a 30-minute novel virtual reality (VR) experience through the Oculus Quest 2 Virtual Reality headset with the aim of measuring changes in: 1) patient-reported stress levels on a survey, 2) blood pressure, 3)heart rate, 4) respiration rate 5) heart rate variability 6) and galvanic skin response in cardiology clinic and cardiac rehabilitation patients.

Phase: N/A
Primary Purpose: Other
Gender: All
Age Group: Adults
Contact: KATHERINE MAKAROFF
Open Actively Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Ladda Douangvila-Chhan
Investigator:
Marcella Calfon Press
Open Actively Recruiting

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart failure and whether it lowers the chances of dying from cardiovascular disease.

People who are in hospital may join the study soon after being treated for their heart attack. Participants are put into 2 groups by chance. One group takes 1 empagliflozin tablet a day. The other group takes 1 placebo tablet a day. Placebo tablets look like empagliflozin tablets but do not contain any medicine. All participants continue their standard treatment. Empagliflozin belongs to a class of medicines known as SGLT-2 inhibitors. Empagliflozin is a medicine that helps people with type 2 diabetes to lower their blood sugar. Researchers think that empagliflozin might also help people after heart attack who are at risk for heart failure, whether or not they have diabetes. Participants are in the study for about 1 to 2 years. During this time, there are about 4 visits inperson, 2 visits are done either by phone or by use of an mobile application. Results between the empagliflozin and placebo groups are compared. The doctors also regularly check the general health of the participants.

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Ladda Douangvila-Chhan
Investigator: Eric H. Yang, MD
Open Actively Recruiting

Electrophysiological Effects of Transcutaneous Vagal Nerve Stimulation

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Open Actively Recruiting

Validation of Smart Syringe for measuring Activated Clotting Time (ACT), Hematocrit and Hemoglobin (H&H)

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Suzan Khalil
Investigator: Ali Nsair, MD
Open Actively Recruiting

Acute Effects of TCIG vs ECIG in PLWH

Randomized controlled trial of acute use of electronic cigarette or tobacco cigarette on parameters of ventricular repolarization and inflammation/oxidative stress.

Phase: N/A
Primary Purpose: Basic Science
Gender: All
Age Group: Adults
Contact: ISABELLE RUEDISUELI
Open Actively Recruiting

Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias

The purpose of this research study is to examine the effect of cardiac sympathetic denervation (CSD) surgery on life threatening abnormal heart rhythms called ventricular tachycardia or ventricular fibrillation that can lead to sudden cardiac death. Subjects will be asked to participate in this research study if they have recurrent ventricular tachycardia (at least one ICD shock for ventricular tachycardia) and have undergone at least one catheter ablation procedure or have ventricular tachycardia or fibrillation that is not ablatable. The goal of this study is to determine whether cardiac sympathetic denervation can prevent these abnormal heart rhythms from occurring and therefore, prevent, ICD shocks which are not only painful, but have been shown to reduce quality of life and/or lead to depression, particularly in the period immediately after the shock.

Phase: Phase 3
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Julie Sorg
Open Actively Recruiting

BioVentrix Revivent TC™ System Clinical Study

A prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System, with 2:1 study vs. active concurrent control group allocation ratio. This study will include 126 patients of which 84 patients will be treated with the investigational device and 42 patients will be included in an active control group.

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Suzan Khalil
Investigator: Ali Nsair, MD
Open Actively Recruiting

Ferumoxytol-Enhanced Cardiac MRI for Ischemic Heart Disease

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Kim-Lien Nguyen
Investigator:
Kim-Lien Nguyen
Open Actively Recruiting

A Study to Evaluate the Effect of Vagus Nerve Stimulation in Patients Undergoing VT Ablation

Vagus nerve stimulation (VNS) has been shown to be beneficial in multiple studies including heart failure. The goal of this clinical investigation is to gain additional information about how vagus nerve stimulation relates to abnormal heart rhythms. The outcomes of this study will help researchers design new therapies for patients that have complex and life-threatening ventricular arrhythmias.

Phase: N/A
Primary Purpose: Basic Science
Gender: All
Age Group: Adults
Contact: Julie Sorg
Open Actively Recruiting

Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli

This study is a prospective, multicenter, randomized (1:1) controlled comparative effectiveness trial of a transseptal approach to left ventricular ablation compared to a retrograde aortic approach to prevent cerebral emboli and neurocognitive decline in adults with ventricular tachycardia (VT) and/or premature ventricular contractions (PVCs).

Phase: N/A
Primary Purpose: Prevention
Gender: All
Contact: Julie Sorg
Open Actively Recruiting

Smoking and Ventricular Repolarization

Randomized controlled trial of acute use of electronic cigarette or tobacco cigarette on parameters of ventricular repolarization.

Phase: N/A
Primary Purpose: Basic Science
Gender: All
Age Group: Adults
Contact: ISABELLE RUEDISUELI
Open Actively Recruiting

Use of a Wearable Sweat Sensor to Detect Electrolytes and Biomarkers in Patients with Heart Failure

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Tzung Hsiai
Open Actively Recruiting

Impact of Endothelin-1 on the Development of Cardiac Allograft Vasculopathy in Heart Transplant Recipients

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Rushi Parikh
Open Actively Recruiting

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.

Phase: Phase III
Primary Purpose: Prevention
Gender: All
Age Group: Adults
Contact: Ladda Douangvila-Chhan
Investigator: Eric H. Yang, MD
Open Actively Recruiting

Hemodynamic-GUIDEd Management of Heart Failure

The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for future HF events or mortality.

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Sandra Rodriguez
Investigator: Ali Nsair, MD
Open Actively Recruiting

E-cigarettes and monocytes

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Holly Middlekauff
Open Actively Recruiting

A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation

This is a randomized, double-blind, placebo-controlled study in patients with dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA). The study will further evaluate a dose level of study drug (ARRY-371797) that has shown preliminary efficacy and safety in this patient population. After the primary analysis has been performed, eligible patients may receive open-label treatment with ARRY-371797.

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Open Actively Recruiting

FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study

This clinical investigation is intended to demonstrate the safety and effectiveness of ventricular ablation therapy using the FlexAbility Sensor Enabled Ablation Catheter in patients with drug-refractory monomorphic ventricular tachycardia in whom ventricular tachycardia recurs despite antiarrhythmic drug therapy or when antiarrhythmic drugs are not tolerated or desired.

Phase: Phase III/IV
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Julie Sorg